SAGE Journals Online
Advertisement
Sign In to gain access to subscriptions and/or personal tools.

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Advertisement

Sign In to gain access to subscriptions and/or personal tools.
Journal of Cardiovascular Pharmacology and Therapeutics
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
1074248409338930v1
14/3/180    most recent
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Jung, J.-H.
Right arrow Articles by Jang, Y.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jung, J.-H.
Right arrow Articles by Jang, Y.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

The Effect of Intracoronary Nicorandil on Coronary Myocardial Bridging

Jae-Hun Jung, MD

Cardiovascular Division, Department of Internal Medicine, Hallym University Medical Center, Seoul, Republic of Korea

Pil-Ki Min, MD, PhD

Cardiology Division, Department of Internal Medicine, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea

Chong Won Sung, MD

Cardiovascular Division, Department of Internal Medicine, Hallym University Medical Center, Seoul, Republic of Korea

Sang-Hak Lee, MD, PhD

Cardiovascular Division of Yonsei Cardiovascular Center and Cardiovascular Research Institute, Yonsei University College of Medicine, Seoul, Republic of Korea

Seonghoon Choi, MD

Cardiovascular Division, Department of Internal Medicine, Hallym University Medical Center, Seoul, Republic of Korea

Jung Rae Cho, MD

Cardiovascular Division, Department of Internal Medicine, Hallym University Medical Center, Seoul, Republic of Korea

Namho Lee, MD, PhD

Cardiovascular Division, Department of Internal Medicine, Hallym University Medical Center, Seoul, Republic of Korea

Kyoung-Ha Park, MD

Cardiovascular Division, Department of Internal Medicine, Hallym University Medical Center, Seoul, Republic of Korea

Min-Kyu Kim, MD, PhD

Cardiovascular Division, Department of Internal Medicine, Hallym University Medical Center, Seoul, Republic of Korea

Woo Jung Park, MD, PhD

Cardiovascular Division, Department of Internal Medicine, Hallym University Medical Center, Seoul, Republic of Korea

Yangsoo Jang, MD, PhD

Cardiovascular Division of Yonsei Cardiovascular Center and Cardiovascular Research Institute, Yonsei University College of Medicine, Seoul, Republic of Korea, jangys1212{at}yuhs.ac

Medical treatments of coronary myocardial bridging (CMB) generally include β-blockers and calcium channel blockers. Nitrates are avoided because symptoms may worsen. Nicorandil is a hybrid of a nitrate and a potassium channel opener. However, the effect of nicorandil on CMB is unknown. We analyzed nicorandil reactivity at the site with CMB in 51 patients. Maximal and minimal diameters of CMB were measured by quantitative angiography at baseline and at 60 seconds after intracoronary administration of 200 mg nicorandil. The maximal diameter during diastole increased from 2.15 + 0.42 mm to 2.34 + 0.44 mm after administration of nicorandil (P < .001), and the minimal diameter during systole increased from 1.24 + 0.63 mm to 1.67 + 0.64 mm (P < .001). Thus, nicorandil reduced the percentage vessel narrowing from 44.0 + 26.1% to 30.3 + 21.2% (P < .001). In 22 patients, we also evaluated the effect of nitroglycerin. The maximal diameter during diastole increased from 2.25 + 0.47 mm to 2.51 + 0.44 mm after administration of nitroglycerin (P < .019), and the minimal diameter during systole decreased from 1.28 + 0.64 mm to 1.14 + 0.60 mm (P = .276). Thus, nitroglycerin augmented the percentage vessel narrowing from 44.9% + 25.0% to 56.0% + 23.5% (P = .023). These results indicate that intracoronary administration of nicorandil could dilate coronary arteries during diastole as well as systole in patients with CMB during coronary angiography.

Key Words: angina pectoris • myocardial bridging • nicorandil

This version was published on September 1, 2009

Journal of Cardiovascular Pharmacology and Therapeutics, Vol. 14, No. 3, 180-184 (2009)
DOI: 10.1177/1074248409338930


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?




Advertisement